MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Free Cash flow
-$68,510K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Maturities of marketable securit...
Prepaid expenses and other curre...
Proceeds from exercise of stock ...
Others
Negative Cash Flow Breakdown
Purchases of marketable securiti...
Research and development expense...
Research and development expense...
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Income tax expense
-
-
-
0
License and collaboration revenue
490
31,738
114,109
25,634
Research and development expenses-External Research And Development Expenses
31,566
30,077
34,816
107,879
Research and development expenses-Employee Related Expenses
31,955
32,867
32,864
84,502
General and administrative expenses-External General And Administrative Expenses
9,561
13,366
10,054
18,265
General and administrative expenses-Employee Related Expenses
12,703
11,951
12,546
30,578
Facility and information technology related expenses
15,441
14,438
15,017
44,076
Depreciation and amortization
5,410
5,605
5,668
16,626
Stock-based compensation
19,278
19,044
20,448
73,796
Interest and other income
7,487
9,867
10,640
33,093
Other segment items
4,741
8,575
-250,961
7,294
Net loss
-122,678
-94,318
244,297
-112,728
Depreciation and amortization
5,410
5,605
5,668
5,560
Amortization of investment discount (premiums)
2,605
2,763
3,258
4,233
In-process research and development charge
-
-
0
14,507
Amortization of debt discount
64
35
-
-
Stock-based compensation expense
19,278
19,044
20,448
22,747
Change in operating lease right-of-use assets
2,561
2,532
2,518
2,573
Change in fair value of derivative liabilities
-4,200
2,500
50
-2,757
Change in fair value of contingent consideration liabilities
205
-514
765
-1,000
Change in fair value of non-controlling equity investments
338
16
-3,329
4,937
Realized loss (gain) on sale of marketable securities
-
-
0
-399
Loss (gain) on disposal of property and equipment
-44
-
-
-
Gain on sale of equity method investment
455
-
255,146
-
Prepaid expenses and other current assets
-29,533
31,861
-59
-1,625
Accounts payable
1,214
2,216
1,194
-1,589
Accrued expenses and other liabilities
1,315
-16,258
14,298
1,977
Operating lease liabilities
-3,529
-3,494
-3,500
-3,383
Deferred revenue
-304
-6,355
-113,820
-5,661
Other long-term liabilities
-11
134
-91
-93
Net cash provided by (used in) operating activities
-66,096
-128,513
-83,289
-81,479
Purchases of property and equipment
2,414
2,232
3,734
5,011
Purchases of marketable securities
180,916
153,792
361,038
175,643
Maturities of marketable securities
173,000
181,293
218,033
240,644
Proceeds from sale of marketable securities
-
-
0
5,743
Cash paid for acquisition, net
-
-
0
78
Proceeds from sale of equity method investment
455
-
255,146
-
Net cash provided by (used in) investing activities
-9,875
25,269
108,407
65,655
Proceeds from issuance of common shares and pre-funded warrants, net of issuance costs
0
0
0
0
Proceeds from issuances of stock under espp
0
1,510
0
1,263
Equipment financings, net
-
-
0
0
Proceeds from exercise of stock options
7,523
2,025
1,886
412
Proceeds from the issuance of debt, net of fees paid to lender
0
93,886
-
-
Proceeds from private stock issuance
-
-
0
-
Payments of debt issuance costs
0
813
-
-
Net cash provided by (used in) financing activities
7,523
96,608
1,886
1,675
Net change in cash, cash equivalents and restricted cash
-68,448
-6,636
27,004
-14,149
Cash, cash equivalents and restricted cashbeginning of period
294,984
301,620
274,616
290,111
Cash, cash equivalents and restricted cashend of period
226,536
294,984
301,620
274,616
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Proceeds from exercise of
stock options
$7,523K
(204.08%↑ Y/Y)
Net cash provided by
(used in) financing...
$7,523K
(-98.41%↓ Y/Y)
Net change in cash,
cash equivalents and...
-$68,448K
(-4985.29%↓ Y/Y)
Canceled cashflow
$7,523K
Prepaid expenses and
other current assets
-$29,533K
(-944.68%↓ Y/Y)
Stock-based compensation
expense
$19,278K
(-62.24%↓ Y/Y)
Depreciation and
amortization
$5,410K
(-51.11%↓ Y/Y)
Change in fair value of
derivative liabilities
-$4,200K
(-223.28%↓ Y/Y)
Change in operating
lease right-of-use...
$2,561K
(-51.65%↓ Y/Y)
Accrued expenses and
other liabilities
$1,315K
(115.31%↑ Y/Y)
Accounts payable
$1,214K
(-81.13%↓ Y/Y)
Change in fair value of
contingent consideration...
$205K
(272.73%↑ Y/Y)
Amortization of debt discount
$64K
Loss (gain) on
disposal of property and...
-$44K
Maturities of marketable
securities
$173,000K
(-54.93%↓ Y/Y)
Proceeds from sale of
equity method...
$455K
Net cash provided by
(used in) operating...
-$66,096K
(63.35%↑ Y/Y)
Net cash provided by
(used in) investing...
-$9,875K
(96.66%↑ Y/Y)
Canceled cashflow
$63,824K
Canceled cashflow
$173,455K
Interest and other income
$7,487K
License and
collaboration revenue
$490K
Net loss
-$122,678K
(42.01%↑ Y/Y)
Purchases of marketable
securities
$180,916K
(-73.12%↓ Y/Y)
Canceled cashflow
$7,977K
Operating lease
liabilities
-$3,529K
(46.71%↑ Y/Y)
Amortization of investment
discount (premiums)
$2,605K
(-69.23%↓ Y/Y)
Gain on sale of equity
method investment
$455K
Change in fair value of
non-controlling equity...
$338K
(-85.52%↓ Y/Y)
Deferred revenue
-$304K
(98.09%↑ Y/Y)
Other long-term
liabilities
-$11K
(92.47%↑ Y/Y)
Purchases of property and
equipment
$2,414K
(-61.07%↓ Y/Y)
Research and development
expenses-Employee Related...
$31,955K
Research and development
expenses-External Research And...
$31,566K
Stock-based compensation
$19,278K
Facility and information
technology related...
$15,441K
General and
administrative...
$12,703K
General and
administrative...
$9,561K
Depreciation and
amortization
$5,410K
(-51.11%↓ Y/Y)
Other segment items
$4,741K
Buy us a coffee
Beam Therapeutics Inc. (BEAM)
Beam Therapeutics Inc. (BEAM)